Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research • 02/24/26
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 02/23/26
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate CancerBusiness Wire • 02/23/26
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate CancerPRNewsWire • 02/23/26
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 02/09/26
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical MilestonesBusiness Wire • 01/12/26
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/26
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development ProgramBusiness Wire • 12/16/25
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness Wire • 11/19/25
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety ProfileBusiness Wire • 11/09/25
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare ConferenceBusiness Wire • 11/07/25
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsBusiness Wire • 11/05/25
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis DeltaBusiness Wire • 11/03/25
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025Business Wire • 10/22/25
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate CancerBusiness Wire • 10/09/25
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?Zacks Investment Research • 10/09/25
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025Business Wire • 10/07/25
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/25
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness Wire • 08/25/25